Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer

The requested reference [d79a8f4e0c9722383c3ad1f1de780d57b3bf961c] no longer exists in our database. It has been replaced by the current reference: [05e637eb8ec52afbd8d45ac5ce1ea81db7d01f23]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic NSCLC.
Epistemonikos ID: b38f5b01bd9031be6a5ec7e8631108e006b24b88
First added on: May 08, 2024